CNSY · Cerenome, Inc.
The AI's read
The trial has moved ahead, and early safety results give Cerenome a reason to keep testing REYOBIQ. The report gives safety findings, not proof that the treatment helps patients. The company also reported cash, secured financing, and money raised through share sales, leaving the update without a clear direction.